Cargando…
Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease
Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal dis...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459464/ https://www.ncbi.nlm.nih.gov/pubmed/28582462 http://dx.doi.org/10.1371/journal.pone.0178971 |
_version_ | 1783241971679100928 |
---|---|
author | Kohara, Marina Masuda, Takahiro Shiizaki, Kazuhiro Akimoto, Tetsu Watanabe, Yuko Honma, Sumiko Sekiguchi, Chuji Miyazawa, Yasuharu Kusano, Eiji Kanda, Yoshinobu Asano, Yasushi Kuro-o, Makoto Nagata, Daisuke |
author_facet | Kohara, Marina Masuda, Takahiro Shiizaki, Kazuhiro Akimoto, Tetsu Watanabe, Yuko Honma, Sumiko Sekiguchi, Chuji Miyazawa, Yasuharu Kusano, Eiji Kanda, Yoshinobu Asano, Yasushi Kuro-o, Makoto Nagata, Daisuke |
author_sort | Kohara, Marina |
collection | PubMed |
description | Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal disease (ESRD) patients remains unclear. This study enrolled 90 ESRD patients receiving chronic hemodialysis who were categorized into low- and high-FGF21 groups by the median value. We investigated the association between circulating FGF21 levels and the cardiovascular event and mortality during a median follow-up period of 64 months. A Kaplan-Meier analysis showed that the mortality rate was significantly higher in the high-FGF21 group than in the low-FGF21 group (28.3% vs. 9.1%, log-rank, P = 0.034), while the rate of cardiovascular events did not significantly differ between the two groups (30.4% vs. 22.7%, log-rank, P = 0.312). In multivariable Cox models adjusted a high FGF21 level was an independent predictor of all-cause mortality (hazard ratio: 3.98; 95% confidence interval: 1.39–14.27, P = 0.009). Higher circulating FGF21 levels were associated with a high mortality rate, but not cardiovascular events in patient with ESRD, suggesting that circulating FGF21 levels serve as a predictive marker for mortality in these subjects. |
format | Online Article Text |
id | pubmed-5459464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54594642017-06-15 Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease Kohara, Marina Masuda, Takahiro Shiizaki, Kazuhiro Akimoto, Tetsu Watanabe, Yuko Honma, Sumiko Sekiguchi, Chuji Miyazawa, Yasuharu Kusano, Eiji Kanda, Yoshinobu Asano, Yasushi Kuro-o, Makoto Nagata, Daisuke PLoS One Research Article Fibroblast growth factor 21 (FGF21) is an endocrine factor that regulates glucose and lipid metabolism. Circulating FGF21 predicts cardiovascular events and mortality in type 2 diabetes mellitus, including early-stage chronic kidney disease, but its impact on clinical outcomes in end-stage renal disease (ESRD) patients remains unclear. This study enrolled 90 ESRD patients receiving chronic hemodialysis who were categorized into low- and high-FGF21 groups by the median value. We investigated the association between circulating FGF21 levels and the cardiovascular event and mortality during a median follow-up period of 64 months. A Kaplan-Meier analysis showed that the mortality rate was significantly higher in the high-FGF21 group than in the low-FGF21 group (28.3% vs. 9.1%, log-rank, P = 0.034), while the rate of cardiovascular events did not significantly differ between the two groups (30.4% vs. 22.7%, log-rank, P = 0.312). In multivariable Cox models adjusted a high FGF21 level was an independent predictor of all-cause mortality (hazard ratio: 3.98; 95% confidence interval: 1.39–14.27, P = 0.009). Higher circulating FGF21 levels were associated with a high mortality rate, but not cardiovascular events in patient with ESRD, suggesting that circulating FGF21 levels serve as a predictive marker for mortality in these subjects. Public Library of Science 2017-06-05 /pmc/articles/PMC5459464/ /pubmed/28582462 http://dx.doi.org/10.1371/journal.pone.0178971 Text en © 2017 Kohara et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kohara, Marina Masuda, Takahiro Shiizaki, Kazuhiro Akimoto, Tetsu Watanabe, Yuko Honma, Sumiko Sekiguchi, Chuji Miyazawa, Yasuharu Kusano, Eiji Kanda, Yoshinobu Asano, Yasushi Kuro-o, Makoto Nagata, Daisuke Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title_full | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title_fullStr | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title_full_unstemmed | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title_short | Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
title_sort | association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459464/ https://www.ncbi.nlm.nih.gov/pubmed/28582462 http://dx.doi.org/10.1371/journal.pone.0178971 |
work_keys_str_mv | AT koharamarina associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT masudatakahiro associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT shiizakikazuhiro associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT akimototetsu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT watanabeyuko associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT honmasumiko associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT sekiguchichuji associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT miyazawayasuharu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT kusanoeiji associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT kandayoshinobu associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT asanoyasushi associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT kuroomakoto associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease AT nagatadaisuke associationbetweencirculatingfibroblastgrowthfactor21andmortalityinendstagerenaldisease |